Benjamin Hohl, serving as the Chief Financial Officer for Enliven Therapeutics, Inc. (NASDAQ: ELVN), executed a sale of 6,018 shares of the company's common stock on June 17, 2026. The total value derived from this transaction was $263,577. The shares were sold at prices fluctuating between $42.295 and $44.945 per share. These sales were facilitated under the framework of a Rule 10b5-1 trading plan, which Mr. Hohl initially adopted on March 18, 2026.
The timing of this sale coincides with a period of significant market activity for Enliven Therapeutics. The company's shares have been trading near their 52-week high of $48.53, reflecting a substantial 193% return for the year-to-date period. The biotech firm currently commands a market capitalization of $2.8 billion. Financial data indicates that the company maintains a stronger position with more cash on its balance sheet than debt.
Mr. Hohl's recent sale activity follows a prior acquisition of the same number of shares. Prior to the sale, he acquired 6,018 shares of common stock through the exercise of stock options at a price of $2.48 per share, totaling $14,924. These options were fully vested and exercisable at the time of the transaction. Following the sale, Mr. Hohl directly holds 51,000 shares of Enliven Therapeutics common stock. A portion of these holdings consists of restricted stock units (RSUs), which represent contingent rights to receive shares based on specific vesting schedules and conditions.
The Form 4 filing detailing these transactions was submitted to the Securities and Exchange Commission (SEC) on June 22, 2026. This filing provides the regulatory framework for tracking insider ownership changes within the company.
Enliven Therapeutics has recently been involved in significant capital raising activities. The company completed a public offering that raised approximately $460 million. This upsized offering involved the sale of 10,533,334 shares of common stock at $37.50 per share, which included additional shares from the underwriters' option. The company also offered pre-funded warrants to purchase 1,733,333 shares at a slightly lower price per warrant. Earlier in the process, Enliven Therapeutics had announced the pricing of this offering at $37.50 per share for 8,933,334 shares. Additionally, the company launched a $250 million stock offering, granting underwriters a 30-day option for more shares.
On the clinical front, Enliven Therapeutics reported positive results from its Phase 1 trial for its leukemia drug candidate, ELVN-001. The trial, part of the ENABLE study, showed promising outcomes in patients with chronic myeloid leukemia. Updated data revealed a 61% overall major molecular response, with 48% achieving this response by 24 weeks in the Phase 1b cohort. These developments provide insight into Enliven Therapeutics' recent activities and progress in its drug pipeline.